litlas
Log inCreate account

Koen Andries

Active 1978–2024

76
Papers
18,180
Citations
70
h-index
75
i10-index

Citations

Citations per year for Koen Andries1981: 1 citations1982: 1 citations1983: 1 citations1987: 3 citations1988: 1 citations1989: 2 citations1990: 6 citations1991: 20 citations1992: 26 citations1993: 56 citations1994: 26 citations1995: 55 citations1996: 47 citations1997: 50 citations1998: 50 citations1999: 68 citations2000: 40 citations2001: 59 citations2002: 40 citations2003: 40 citations2004: 105 citations2005: 67 citations2006: 62 citations2007: 99 citations2008: 151 citations2009: 156 citations2010: 171 citations2011: 179 citations2012: 184 citations2013: 235 citations2014: 294 citations2015: 232 citations2016: 234 citations2017: 212 citations2018: 219 citations2019: 643 citations2020: 645 citations2021: 477 citations2022: 410 citations2023: 235 citations2024: 375 citations2025: 130 citations2026: 7 citations1984–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,402 citing papers, 25.1% of this breakdownUnited Kingdom: 377 citing papers, 6.7% of this breakdownIndia: 350 citing papers, 6.3% of this breakdownChina: 344 citing papers, 6.2% of this breakdownBelgium: 268 citing papers, 4.8% of this breakdownSouth Africa: 257 citing papers, 4.6% of this breakdownGermany: 194 citing papers, 3.5% of this breakdownFrance: 194 citing papers, 3.5% of this breakdownItaly: 172 citing papers, 3.1% of this breakdownSwitzerland: 150 citing papers, 2.7% of this breakdownNetherlands: 131 citing papers, 2.3% of this breakdownAustralia: 124 citing papers, 2.2% of this breakdown
0%25.1%Other 29%

Institutions

Fields

  • Medicine68.3%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology5.2%
  • Chemistry4.2%
  • Computer Science3.6%
  • Pharmacology, Toxicology and Pharmaceutics1.5%
  • Other3.1%

Topics

  • Tuberculosis Research and Epidemiology16%
  • Mycobacterium research and diagnosis7.3%
  • HIV/AIDS drug development and treatment5.8%
  • HIV Research and Treatment4.9%
  • Cancer therapeutics and mechanisms4.6%
  • Pneumocystis jirovecii pneumonia detection and treatment3.3%
  • Other58.1%

Coauthors

All papers

Open in search
  1. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

    Authors: Koen Andries, Peter Verhasselt, Jérôme Guillemont, Hinrich W. H. Göhlmann, Jean‐Marc Neefs, Hans Christian Winkler, Jef Van Gestel, Philip Timmerman, Min Zhu, Ennis Lee, Peter Williams, Didier de Chaffoy, Emma Huitric, Sven Hoffner, Emmanuelle Cambau, C. Truffot-Pernot, Nacer Lounis, Vincent Jarlier - Science 2004 cited by 2,169

  2. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

    Authors: Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, Jorge M. de los Rios, Eduardo Gotuzzo, I. А. Vаsilyevа, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P. G. van Heeswijk, Brian Dannemann - New England Journal of Medicine 2014 cited by 752

  3. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

    Authors: Koen Andries, Cristina Villellas, Nele Coeck, Kim Thys, Tom Gevers, Luc Vranckx, Nacer Lounis, Bouke C. de Jong, Anil Koul - PLoS ONE 2014 cited by 431

  4. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

    Authors: Alexander S. Pym, Andreas H. Diacon, Shenjie Tang, Francesca Conradie, Manfred Danilovitš, Charoen Chuchottaworn, I. А. Vаsilyevа, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Rolf P. G. van Heeswijk, Brian Dannemann - European Respiratory Journal 2015 cited by 341

  5. Towards a new combination therapy for tuberculosis with next generation benzothiazinones

    Authors: Vadim Makarov, Benoît Lechartier, Ming Zhang, João Neres, Astrid M. van der Sar, Susanne A. Raadsen, Ruben C. Hartkoorn, O. B. Ryabova, Anthony Vocat, Laurent A. Décosterd, Nicolas Widmer, Thierry Buclin, Wilbert Bitter, Koen Andries, Florence Pojer, Paul J. Dyson, Stewart T. Cole - EMBO Molecular Medicine 2014 cited by 385

  6. The challenge of new drug discovery for tuberculosis

    Authors: Anil Koul, Éric Arnoult, Nacer Lounis, Jérôme Guillemont, Koen Andries - Nature 2011 cited by 1,047

  7. The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

    Authors: Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, R. F. Patientia, Roxana Rustomjee, Liesl Page‐Shipp, Christoffel Pistorius, René Krause, Mampedi Bogoshi, Gavin Churchyard, Amour Venter, Jenny Allen, Juan Carlos Palomino, Tine De Marez, Rolf P. G. van Heeswijk, Nacer Lounis, Paul Meyvisch, Johan Verbeeck, Wim Parys, K. De Beule, Koen Andries, David F. Mc Neeley - New England Journal of Medicine 2009 cited by 839

  8. Diarylquinolines target subunit c of mycobacterial ATP synthase

    Authors: Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Stanojević-Ristić, Holger Lill, Ismet Dorange, Jérôme Guillemont, Dirk Bald, Koen Andries - Nature Chemical Biology 2007 cited by 548

  9. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

    Authors: Deepak V. Almeida, Thomas R. Ioerger, Sandeep Tyagi, Si-Yang Li, Khisimuzi Mdluli, Koen Andries, J Grosset, J.C. Sacchettini, Eric L. Nuermberger - Antimicrobial Agents and Chemotherapy 2016 cited by 213

  10. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism

    Authors: Anil Koul, Luc Vranckx, Neeraj Dhar, Hinrich W. H. Göhlmann, Emre Özdemir, Jean‐Marc Neefs, Melanie Schulz, Ping Lü, Ejvind Mørtz, John D. McKinney, Koen Andries, Dirk Bald - Nature Communications 2014 cited by 293

  11. Bactericidal mode of action of bedaquiline

    Authors: Kiel Hards, Jennifer Robson, Michael Berney, Lisa E. Shaw, Dirk Bald, Anil Koul, Koen Andries, Gregory M. Cook - Journal of Antimicrobial Chemotherapy 2015 cited by 232

  12. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

    Authors: Scott M. Irwin, Brendan Prideaux, Edward Lyon, Matthew Zimmerman, Elizabeth J. Brooks, Christopher Schrupp, Chao Chen, Matthew J. Reichlen, Bryce Asay, Martin I. Voskuil, Eric L. Nuermberger, Koen Andries, Michael A. Lyons, Véronique Dartois, Anne J. Lenaerts - ACS Infectious Diseases 2016 cited by 155

  13. Rates and Mechanisms of Resistance Development inMycobacterium tuberculosisto a Novel Diarylquinoline ATP Synthase Inhibitor

    Authors: Emma Huitric, Peter Verhasselt, A. Koul, Koen Andries, Sven Hoffner, Dan I. Andersson - Antimicrobial Agents and Chemotherapy 2009 cited by 216

  14. Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis

    Authors: Anil Koul, Luc Vranckx, Najoua Dendouga, Wendy Balemans, Ilse Van den Wyngaert, Karen Vergauwen, Hinrich W. H. Göhlmann, Rudy Willebrords, Alain Poncelet, Jérôme Guillemont, Dirk Bald, Koen Andries - Journal of Biological Chemistry 2008 cited by 367

  15. Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action

    Authors: Katherine A. Sacksteder, Marina Protopopova, Clifton E. Barry, Koen Andries, Carol A. Nacy - Future Microbiology 2012 cited by 275

  16. Unexpected high prevalence of resistance-associatedRv0678variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline

    Authors: Cristina Villellas, Nele Coeck, Conor J. Meehan, Nacer Lounis, Bouke C. de Jong, Leen Rigouts, Koen Andries - Journal of Antimicrobial Chemotherapy 2016 cited by 171

  17. Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models

    Authors: Andrés Obregón‐Henao, Kimberly Arnett, Marcela Henao‐Tamayo, Lisa M. Massoudi, Elizabeth Creissen, Koen Andries, Anne J. Lenaerts, Diane Ordway - Antimicrobial Agents and Chemotherapy 2015 cited by 120

  18. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

    Authors: Kalyan Das, Arthur D. Clark, Paul Lewi, Jan Heeres, Marc R. de Jonge, Lucien M. H. Koymans, H. Maarten Vinkers, Frederik F. D. Daeyaert, Donald Ludovici, Michael J. Kukla, Bart De Corte, Robert W. Kavash, Chih Y. Ho, Ye Hong, Mark. A. Lichtenstein, Koen Andries, Rudi Pauwels, Marie-Pierre de Béthune, Paul L. Boyer, Patrick K. Clark, Stephen H. Hughes, Paul A. J. Janssen, Eddy Arnold - Journal of Medicinal Chemistry 2004 cited by 511

  19. Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910

    Authors: Anne J. Lenaerts, Donald R. Hoff, Sahar Aly, Stefan Ehlers, Koen Andries, Luis Cantarero, Ian M. Orme, Randall J. Basaraba - Antimicrobial Agents and Chemotherapy 2007 cited by 259

  20. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress

    Authors: Ping Lü, Marieke H. Heineke, Anil Koul, Koen Andries, Gregory M. Cook, Holger Lill, Rob J. M. van Spanning, Dirk Bald - Scientific Reports 2015 cited by 120

  21. 6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis

    Authors: Amy S.T. Tong, Peter J. Choi, Adrian Blaser, Hamish S. Sutherland, Sophia K. Y. Tsang, Jérôme Guillemont, Magali Motte, Christopher B. Cooper, Koen Andries, Walter Van den Broeck, Scott G. Franzblau, Anna M. Upton, William A. Denny, Brian D. Palmer, Daniel Conole - ACS Medicinal Chemistry Letters 2017 cited by 83

  22. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

    Authors: Andreas H. Diacon, Peter R. Donald, Alexander S. Pym, Martin P. Grobusch, R. F. Patientia, Russel Mahanyele, Nonkqubela Bantubani, R. Narasimooloo, Tine De Marez, Rolf van Heeswijk, Nacer Lounis, Paul Meyvisch, Koen Andries, D. F. McNeeley - Antimicrobial Agents and Chemotherapy 2012 cited by 380

  23. In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)

    Authors: Paul A. J. Janssen, Paul Lewi, Eddy Arnold, Frits Daeyaert, Marc R. de Jonge, Jan Heeres, Luc Koymans, Maarten Vinkers, Jérôme Guillemont, Élisabeth Pasquier, Mike Kukla, D.W. Ludovici, Koen Andries, Marie‐Pierre de Béthune, Rudi Pauwels, Kalyan Das, Art D. Clark, Yulia Volovik Frenkel, Stephen H. Hughes, Bart Medaer, Fons De Knaep, Hilde Bohets, Fred De Clerck, Ann Lampo, Peter Williams, Paul Stoffels - Journal of Medicinal Chemistry 2004 cited by 342

  24. Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis

    Authors: Rokeya Tasneen, Si-Yang Li, Charles A. Peloquin, Dinesh Taylor, Kathy N. Williams, Koen Andries, Khisimuzi Mdluli, Eric L. Nuermberger - Antimicrobial Agents and Chemotherapy 2011 cited by 210